Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra [1]

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1683-1684

  McGonagle, Dennis ^a,d   Tan, A L ^b   Shankaranarayana, S ^a   Madden, J ^a   Emery, P ^b   McDermott, M F ^c  

^a CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZBROMARONE; C REACTIVE PROTEIN; COLCHICINE; CREATININE; FEBUXOSTAT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; PREDNISOLONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; URATE; URATE OXIDASE; UREA;

ACUTE DISEASE; AGED; ANAMNESIS; ARTHRALGIA; ARTHRITIS; BONE EROSION; BONE RADIOGRAPHY; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INHIBITION; ERYTHEMA; FOLLOW UP; GLOMERULONEPHRITIS; GOUT; HUMAN; JOINT SWELLING; LABORATORY TEST; LETTER; MALE; OSTEOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, GOUTY; CHRONIC DISEASE; FINGER JOINT; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE;

EID: 34548667797     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073759     Document Type: Letter

References (10)

1. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanism of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005;41:925-35.
2. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001;38(4 suppl 10): 13-21.
3. 2-generating peroxisomal urate oxidase. Cancer Res 1996;56:4846-52.
4. Akahoshi T, Murakami Y, Kitasato H. Recent advances in crystal-induced acute inflammation [review]. Curr Opin Rheumatol 2007;19:146-50.
5. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;40:237-41.
6. Murakami Y, Akahoshi T, Hayashi I, Endo H, Hashimoto A, Kono S, et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum 2003;48:2931-41.
7. Roberge CJ, Grassi J, De Medicis R, Frobert Y, Lussier A, Naccache PH, et al. Crystal-neutrophil interactions lead to interleukin-1 synthesis. Agents Actions 1991;34:38-41.
8. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1 ) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987;138:3213-18.
9. So A, Desmedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther, 2007;9:R28 [Epub ahead of print]..
10. Tausche AK, Richter K, Grassler A, Hansel S, Roch B, Schroder HE. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 2004;63:1351-2.